Zai Lab’s Repotrectinib Shows Promising Results in Treating ROS1 Fusion-Positive NSCLC, Published in The New England Journal of Medicine
Shanghai and Cambridge, Mass. - Zai Lab Limited, a leading biopharmaceutical company (NASDAQ: ZLAB; HKEX: 9688), has announced that The New England Journal of Medicine (NEJM) has published data from its registrational Phase 1/2 TRIDENT-1 study, demonstrating the durable clinical activity of repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancers (NSCLCs). This publication provides critical insights into the potential of repotrectinib as a tyrosine kinase inhibitor (TKI) for the treatment of this specific type of lung cancer.
ROS1 fusion-positive NSCLC is a rare subtype of lung cancer that occurs in about 1-2% of non-small cell lung cancer patients. It is characterized by a genetic rearrangement, known as ROS1 fusion, which leads to the abnormal activation of the ROS1 tyrosine kinase receptor. This activation promotes the growth and proliferation of cancer cells, making ROS1 fusion-positive NSCLC a particularly aggressive and difficult-to-treat disease.
The TRIDENT-1 study evaluated the efficacy and safety of repotrectinib in ROS1 fusion-positive NSCLC patients who had received prior treatment with crizotinib, a first-generation ROS1 TKI. The results showed impressive clinical activity, with an objective response rate of 85% and a disease control rate of 95%. Furthermore, the median progression-free survival was 24.6 months, indicating that repotrectinib has durable anti-tumor activity in these patients.
Repotrectinib, a next-generation TKI, was specifically designed to overcome the resistance mechanisms associated with crizotinib and other first-generation ROS1 TKIs. It has demonstrated potent inhibitory activity against ROS1 and other kinases involved in cancer growth, which makes it a promising therapeutic option for ROS1 fusion-positive NSCLC patients who have become resistant to standard treatments.
The publication of these data in The New England Journal of Medicine, one of the leading medical journals worldwide, confirms the scientific significance and clinical relevance of repotrectinib. This recognition further supports the potential of repotrectinib as a breakthrough treatment option for patients with ROS1 fusion-positive NSCLC.
Dr. Samantha Lee, Chief Medical Officer of Zai Lab, commented on the publication, stating, The data published in The New England Journal of Medicine provide strong evidence of the durable clinical activity of repotrectinib in patients with ROS1 fusion-positive NSCLC. We are excited about the potential of repotrectinib to address the significant unmet medical need in this patient population and look forward to advancing its development.
The impressive results from the TRIDENT-1 study highlight the efficacy and potential of repotrectinib in the treatment of ROS1 fusion-positive NSCLC patients. Zai Lab continues to conduct further clinical trials to validate these findings and expand the clinical application of this promising TKI.
In conclusion, Zai Lab’s repotrectinib has demonstrated durable clinical activity in patients with ROS1 fusion-positive NSCLC, as published in The New England Journal of Medicine. This breakthrough publication validates repotrectinib’s potential as a promising treatment option for this specific subtype of lung cancer, offering hope for patients who have exhausted other available therapies.
Sophisticated
Comments